572 related articles for article (PubMed ID: 17295600)
1. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
2. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Fenter TC; Davis EA; Shah MB; Lin PJ
Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
[TBL] [Abstract][Full Text] [Related]
4. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.
Naslund M; Black L; Eaddy M; Batiste LR
Am J Manag Care; 2007 Feb; 13 Suppl 1():S17-22. PubMed ID: 17295601
[TBL] [Abstract][Full Text] [Related]
5. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes in patients treated for enlarged prostate.
Naslund MJ; Issa MM; Grogg AL; Eaddy MT; Black L
Am J Manag Care; 2006 Mar; 12(4 Suppl):S111-6. PubMed ID: 16551204
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
9. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
[TBL] [Abstract][Full Text] [Related]
11. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.
Naslund M; Eaddy MT; Kruep EJ; Hogue SL
Am J Manag Care; 2008 May; 14(5 Suppl 2):S167-71. PubMed ID: 18611091
[TBL] [Abstract][Full Text] [Related]
12. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
[TBL] [Abstract][Full Text] [Related]
14. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
16. 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.
Naslund M; Regan TS; Ong C; Hogue SL
Am J Manag Care; 2008 May; 14(5 Suppl 2):S148-53. PubMed ID: 18611088
[TBL] [Abstract][Full Text] [Related]
17. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
20. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
